Todas las investigaciones
ReclutamientoConfirmatorio terapéutico (Fase III)Intervencionista

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Heterozygous Familial Hypercholesterolemia

This research study is looking at a new medicine called MK-0616, given as a tablet, for adults who have a genetic condition called Heterozygous Familial Hypercholesterolemia (HeFH). This condition causes very high levels of 'bad' cholesterol in the blood. The main goals are to find out how well MK-0616 lowers 'bad' cholesterol (LDL-C) after 24 weeks and to check for any side effects. To do this, some people will receive the new tablet, and others will receive a dummy tablet (placebo), without knowing which they are getting. We will compare these two groups to understand if MK-0616 is effective and safe. This is a common way to test new medicines.

De un vistazo

Estado
Reclutamiento
Fase
Confirmatorio terapéutico (Fase III)
Patrocinador
Merck Sharp & Dohme LLC
Objetivo de inscripción
123
Inicio
25 Sep 2023

¿De qué trata este estudio?

This study is about a new medicine called MK-0616, which is given in tablet form. It's for adults who have a specific health condition known as Heterozygous Familial Hypercholesterolemia, often shortened to HeFH. This is a genetic condition, meaning it's passed down in families, and it causes people to have very high levels of cholesterol in their blood, especially a type called 'LDL-C' or 'bad' cholesterol. High levels of 'bad' cholesterol can increase the risk of heart problems.

The main aim of this study is to see if MK-0616 can help lower this 'bad' cholesterol effectively and safely. To do this fairly, we'll compare it to a 'placebo', which is a dummy tablet that looks the same but contains no medicine. Neither you nor your study doctor will know if you're taking the actual medicine or the placebo. This is called a 'double-blind' study and helps us get the most accurate results by preventing bias.

Researchers will closely watch how much your 'bad' cholesterol changes after 24 weeks on the treatment. They will also keep a close eye on any side effects you might experience. This means they will record any new health problems or discomfort you have during the study. This information is really important to understand if MK-0616 could be a good new medicine for people with HeFH.

Puntos clave

  • This study is testing a new tablet for a genetic high cholesterol condition (HeFH).
  • It aims to see how well the medicine lowers 'bad' cholesterol and if it's safe.
  • Participants will receive either the new medicine or a dummy tablet.
  • Regular clinic visits and blood tests will be part of the study.
  • It includes adults aged 18 and over, both men and women, with HeFH.

¿Quién puede ser elegible?

To join this study, you must be an adult, aged 18 years or older. There is no upper age limit, so people of all adult ages can be considered. Both men and women are welcome to take part in this research.

All participants will need to have a confirmed diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH). This is a specific type of high cholesterol that runs in families. The study team will check your medical history and conduct some tests to make sure you meet all the necessary health requirements for the study. They will also ensure that it's safe for you to take part.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. ¿Tienes 18 años o más?
  2. Do you have a diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH)?
  3. Are you able to take tablets regularly as prescribed?
  4. Are you able to attend regular clinic appointments for check-ups and tests?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you decide to take part, you would be randomly assigned to one of two groups: one group will receive the new medicine, MK-0616, in tablet form, and the other group will receive a dummy tablet (placebo). You won't know which one you're getting, and neither will your study doctor. You'll need to take the tablets as instructed.

Throughout the study, you'll have regular visits to the clinic. At these visits, the study team will take blood samples to measure your cholesterol levels, check your general health, and ask about any side effects you might be experiencing. These assessments are important to see if the medicine is working and if it's safe. The study will last for a period of time, with cholesterol levels checked at various points, particularly at 24 weeks and then again at 52 weeks to see the longer-term effects. There will be follow-up appointments after you stop taking the study medication to ensure your well-being.

Riesgos y beneficios potenciales

Taking part in a study like this means you might benefit from a new treatment for your condition before it's widely available. You'll also receive careful monitoring of your health from the study team. However, there's no guarantee that the new medicine will work for you, or that you'll even receive the active medicine. Like all medicines, MK-0616 might have side effects, and some could be unpleasant or serious. All risks and potential benefits will be explained in detail by the study team. You are completely free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Ubicaciones (6)

Algunas ubicaciones de los sitios son aproximadas. Estamos mejorando esto — por favor verifique con el equipo de prueba antes de viajar.
  • —
    No verificado
    Finlandia
  • —
    No verificado
    Noruega
  • —
    No verificado
    España
  • —
    No verificado
    Países Bajos
  • —
    No verificado
    Chequia
  • —
    No verificado
    Hungría

Preguntas comunes

What is HeFH?

HeFH stands for Heterozygous Familial Hypercholesterolemia. It's a genetic condition that causes very high levels of 'bad' cholesterol (LDL-C) in your blood from birth, making heart problems more likely.

What is 'bad' cholesterol (LDL-C)?

LDL-C is often called 'bad' cholesterol because high levels can lead to a build-up in your arteries, increasing your risk of heart disease.

¿Qué es un 'placebo'?

A placebo is a dummy pill that looks just like the real medicine but contains no active drug. It helps researchers compare the effects of the actual medicine fairly.

Will I know if I'm getting the real medicine?

No, neither you nor your study doctor will know if you're taking the new medicine or the placebo. This is a standard way to get unbiased results.

What happens if I have side effects?

The study team will monitor you closely for any side effects. You should report any new or worsening symptoms, and they will provide care and guidance.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Stud…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.